London – Al Quds Al Arabi: A team of researchers has found a way to prevent or reverse the onset of type 2 diabetes, by studying three different preclinical models.
According to a report published by “Medical Express”, a research team from various institutions, including Yale University School of Medicine “YSM” and Raymond Herzog Laboratory, is currently conducting human feasibility trials with patients with type 2 diabetes, which brings the drug closer to the day when It abandons monitoring and management of diabetes through blood sugar tests, insulin injections, and other drug treatments.
The research team said that the goal of such studies is to provide long-term treatment for people with type 2 diabetes to alleviate and possibly reverse the disease.
Type 2 diabetes affects millions of people worldwide. The long-term condition causes an increase in blood sugar in the bloodstream.
Diabetes is a major cause of blindness, kidney failure, heart attack, stroke and lower limb amputation.
Herzog, MD, associate professor (endocrinology) in the division of internal medicine at Yale University School of Medicine and a member of the National Institutes of Health-funded Yale Diabetes Research Center, is working in his lab to test the effect of ultrasound therapy on blood glucose. “Although we already have a large variety of anti-diabetes drugs available to us to treat elevated glucose levels, we are always looking for new ways to improve insulin sensitivity in diabetes,” Herzog said.
“Unfortunately, there are currently very few drugs that lower insulin levels,” he added. If our ongoing clinical trials and the number of preclinical studies mentioned in this paper confirm that ultrasound can be used to lower insulin and glucose levels, then ultrasound neuromodulation will represent an exciting and completely new addition to the current treatment options for our patients.”
After the reported preclinical studies, the research team participated in additional studies looking at the effects of alternative doses such as the type of ultrasound pulse and duration of treatment. The team is expected to report on those studies later this year.